Tomotherapy archive structure and new software tool for loading and advanced analysis of data contained in it

AbstractAimThe main objective of the study was to analyze the structure of data contained in the archives exported from a tomotherapy treatment planning system. An additional aim was to create an application equipped with a user-friendly interface to enable automatic reading of files and data analysis, also using external algorithms. Analyses had to include image registration, dose deformation and summation.Materials and methodsFiles from the archive exported from the tomotherapy treatment planning system (TPS) were analyzed. Two programs were used to analyze the information contained in the archive files: XML Viewer by MindFusion Limited and HxD hex editor by Maël Hora. To create an application enabling loading and analyzing the data, Matlab by MathWorks, version R2009b, was used.ResultsArchive exported from the TPS is a directory with several files. It contains three types of data: .xml, .img and .sin. Tools available in Matlab offer great opportunities for analysis and transformation of loaded information. Proposed application automates the loading of necessary information and simplifies data handling. Furthermore, the application is equipped with a graphical user interface (GUI). The main application window contains buttons for opening the archives and analyzing the loaded data.ConclusionThe analysis of data contained in the archive exported from the tomotherapy treatment planning system allowed to determine the way and place of saving information of our interest, such as tomography images, structure sets and dose distributions. This enabled us to develop and optimize methods of loading and analyzing this information

Optimization of Single-Sided Lapping Kinematics Based on Statistical Analysis of Abrasive Particles Trajectories

The chapter presents the influence of selected kinematic parameters on the geometrical results of the single-sided lapping process. The optimization of these parameters is aimed at improving the quality and flatness of the machined surfaces. The uniformity of tool wear was assumed as main optimization criterion. Lapping plate wear model was created and in detail was analyzed. A Matlab program was designed to simulate the abrasive particles trajectories and to count their distribution. In addition, the influence of additional guiding movements of the conditioning ring has been verified and the idea of a flexible single-sided lapping system assisted with a robot, which ensures the optimal constant wear over the diameter was presented

Uncertainty study of data-based models of pollutant transport in rivers

River engineeringTransport and fate of pollutants in river

Language Barriers in Health Care Settings: An Annotated Bibliography of Research Literature

Provides an overview of resources related to the prevalence, role, and effects of language barriers and access in health care

MOCVD Grown HgCdTe Heterostructures

HgCdTe heterostructures are widely applied for IR (infrared) detector constructing. Donor‐ and acceptor‐doping researches in (100) and (111) oriented HgCdTe layers grown by MOCVD have been studied. Fully doped HgCdTe heterostructures with acceptor concentration range between 1014 and 5 × 1017 cm-3 and donor concentration range between 1014 and 1 × 1018 cm-3 and without post‐grown annealing have been reported. The electrical and chemical characterizations of HgCdTe structures grown at 360°C on GaAs substrates using DIPTe have been described. Infrared photodiodes with different composition x were constructing on the basis of obtained heterostructures enabling signal detection of any wavelength from 1 µm to above 20 µm covering SWIR, MWIR and LWIR spectral ranges. Presented experimental results show that MOCVD technology enables to grow HgCdTe structures dedicated for HOT devices

Forecasting of the composite dose for organs at risk and solid targets with random movements during different image-guided scenarios of the photon radiation therapy. Solution for the Varian therapeutic line

BACKGROUND: This study aims to develop a useful tool for robust plan analysis which includes the effects of soft tissue deformations on simulated dose distributions. The solution was benchmarked in the light of the commercial method implemented in EclipseTM treatment planning system (TPS). MATERIALS AND METHODS: Study was carried out on data of one patient with prostate-restricted cancer. The workflow of the procedure developed focused on three executive elements: in-house script to create a set of artificial CT images and for movement simulation of the CTV; the VelocityTM software for the calculations of the deformation matrixes and, then, to generate deformed CT sets; the EclipseTM TPS for dose re-calculations and analysis. Two scenarios were examined — first when the re-calculation was done for the original geometry and second, when the isocentre from the original plan geometry was moved according to the movement of the CTV. The dose distributions were analysed on dose volume histograms (DVHs) in the light of the results obtained from the method implemented in the EclipseTM TPS. RESULTS: The DVHs from our methods are more informative than the DVH from commercially implemented tools. For the first scenario, the highest impact on dose uncertainty has boundary positions of the CTV to the CTV-PTV margin. Using the second scenario, it is the relation of the CTV position to the whole body that has the highest effect on dose uncertainty. CONCLUSION: Our method enables a more accurate analysis of the treatment plan robustness than the method currently implemented in EclipseTM TPS

The foetal development of the human osseous labyrinth in a computed tomographic study

A CT study was performed on 8 foetuses aged between 20 and 38 weeks. In foetuses at the 20th week the semicircular canals, the spiral canal of the cochlea and the initial (labyrinthine) part of the facial canal are visible. At week 24 the tympanic part of the facial canal is observed. In the 31st week the cochlea is divided into 2 compartments, and in the 38th week the vestibular aqueduct and osseous labyrinth are seen

Hepatocyte growth factor in exhaled breath and BAL fluid in sarcoidosis

Wstęp: Wątrobowy czynnik wzrostu (HGF) jest silnym mitogenem stymulującym wzrost komórek nabłonka pęcherzyków płucnych. Wyższe stężenia HGF w różnych materiałach biologicznych stwierdzono między innymi w zespole ostrej niewydolności oddechowej (ARDS), u chorych po przebytym zapaleniu płuc i po pneumonektomii. Niekorzystnym zejściem sarkoidozy jest włóknienie płuc. Wątrobowy czynnik wzrostu mógłby być przydatny jako marker pozwalający na rozpoznanie chorych obarczonych ryzykiem włóknienia płuc. Celem pracy była ocena: 1) czy HGF jest wykrywalny w popłuczynach oskrzelowo-pęcherzykowych (BAL) i kondensacie powietrza wydechowego (EBC); 2) czy stężenia HGF w BAL-u i kondensacie chorych na sarkoidozę różnią się od stężeń osób zdrowych; 3) czy istnieją korelacje z parametrami aktywności i wybranymi czynnikami rokowniczymi. Materiał i metody: Zebrano kondensat od 64 i popłuczyny oskrzelowo-pęcherzykowe od 30 chorych na sarkoidozę. Grupę kontrolną stanowiły osoby zdrowe (n = 15 dla EBC, n = 9 dla BAL). Wątrobowy czynnik wzrostu oznaczono immunoenzymatycznie. Wyniki: Stężenia HGF w kondensacie przekroczyły próg detekcji u 62% badanych (56% chorych i 87% zdrowych) i we wszystkich próbkach BAL. Nie stwierdzono różnic w stężeniach w EBC i BAL pomiędzy osobami chorymi i zdrowymi. Nie stwierdzono korelacji pomiędzy HGF w EBC/BALF a stopniem radiologicznym, parametrami czynności płuc, czasem trwania choroby, liczbą nawrotów, odsetkiem limfocytów w BAL, stężeniem enzymu konwertującego angiotensynę i wapnia w surowicy, utratą dobową wapnia z moczem. Wnioski: Wątrobowy czynnik wzrostu jest wykrywalny w BAL i EBC. Jednak brak różnic pomiędzy chorymi na sarkoidozę i osobami zdrowymi oraz brak korelacji z markerami aktywności i czynnikami rokowniczymi uniemożliwiają jego zastosowanie w diagnostyce i monitorowaniu sarkoidozy.Introduction: Hepatocyte growth factor (HGF) is a strong mitogen stimulating lung epithelial cell growth. Elevated levels of HGF have been reported in various biological materials of patients with acute respiratory distress syndrome and in patients recovering from pneumonia or pneumonectomy. Sarcoidosis may be complicated by lung fibrosis. Consequently, HGF could be considered a new biomarker identifying patients with a higher risk of lung fibrosis. The aim of the study was to verify whether: 1. HGF is measurable in bronchoalveolar lavage fluid (BALF) and exhaled breath condensate (EBC); 2. HGF in BALF or EBC is impaired in sarcoidosis; and 3. HGF correlates with chosen activity and prognostic markers. Material and methods: Sixty-four EBC and 30 BALF of sarcoid patients, and 15 and 9 of healthy controls, respectively, were collected for the measurement of HGF using an ELISA test. Results: HGF was detectable in 62% of EBC samples (56% sarcoidosis and 87% of controls) and in all the BALF samples. EBC and BALF concentrations were not different in comparison to the controls. Moreover, no correlation was found between EBC/BALF concentrations and radiological stage, lung function tests, duration of disease, number of relapses, BALF lymphocytes, serum ACE, or serum and urine calcium concentrations. Conclusions: HGF is detectable in BAL and EBC. However, it does not distinguish sarcoidosis patients from healthy subjects. The above, as well as the lack of correlations with various parameters of disease activity and severity rule out EBC/ /BALF HGF as a biomarker for sarcoidosis monitoring

Idiopathic pulmonary fibrosis (IPF) ― common practice in Poland before the “antifibrotic drugs era”

  INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and debilitating lung disease with a median survival time of 3–5 years. For now, pirfenidone (PIR) and nintedanib (NTB) are the only drugs that can slow down the disease’s progression. In Poland, these drugs, although registered for legal use, had not been reimbursed for IPF patients until the end of the year 2016. Aim of the study was to assess what was common practice in terms of diagnosis and treatment in the period before antifibrotic drugs became available for IPF patients in Poland. MATERIAL AND METHODS: We performed a survey among participants of two nationwide pulmonological congresses held in 2016. RESULTS: One hundred and fifty physicians took part in the study. Only 55% of respondents would reach their final diagnosis in collaboration with a radiologist. Just 40% of those sending patients for surgical lung biopsy (SLB) would discuss the case directly with a pathologist. 22% would never refer the patient suspected of having IPF for SLB. 85% believed that bronchoalveolar lavage (BAL) may be useful for diagnosis. 41% of respiratory professionals would not use any drug for the treatment of IPF patients. 23% of physicians would prescribe corticosteroids in high doses (CS), either in monotherapy or in combination with other drugs. Only 43% of respondents would use antacid drugs in case of symptomatic gastro-oesophageal reflux disease (GERD), and only 11% would prescribe these drugs regardless of GERD diagnosis. CONCLUSIONS: The majority of Polish pulmonologists were not supported by radiologists and pathologists in the diagnostic process. Treatment standards were unsatisfactory, mostly due to a lacking of reimbursement regulations. Further education is necessary to improve management of IPF patients in Poland.